Development of genetic vaccines for pathogenic genes: Construction of attenuated vif DNA immunization cassettes

AIDS

Volumn 11, Issue 12, 1997, Pages 1433-1444

  Ayyavoo, Velpandi ^a   Nagashunmugam, Thandavarayan ^b   Boyer, Jean ^a   Mahalingam, Sundarasamy ^a   Fernandas, Laura S ^a   Le, Phong ^b   Lin, Julie ^a   Nguyen, Chau ^a   Chattargoon, Michael ^a   Goedert, James J ^c   Friedman, Harvey ^b   Weiner, David B ^a,b  

^a Department of Pathology ^*  (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cellular and humoral immune responses; HIV vif genotype; Natural pathogen; Transcomplementation; Vaccine

Indexed keywords

DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LIVE VACCINE; VIF PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; MOUSE; NONHUMAN; OPEN READING FRAME; PRIORITY JOURNAL; VIRUS ATTENUATION;

EID: 9844258895     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199712000-00007     Document Type: Article

References (49)

1. Fynan EF, Webter RG, Fuller DH, et al.: DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inocluations. Proc Natl Acad Sci USA 1991, 90:11478-11482.
2. Tang D, DeVit M, Johnston S: Genetic immunization is a simple method for elicting an immune response. Nature 1992, 352: 152-154.
3. Ulmer JB, Donnelly J, Parker SE, et al.: Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993, 259:1745-1749.
4. Wang B, Ugen K, Srikantan V, et al.: Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1993, 90:4156-4160.
5. Fuller DH, Haynes JR: A qualitative progression in HIV type 1 glycoprotein 120-specific cytotoxic cellular and humoral immune responses in mice receiving a DNA-based glycoprotein 120 vaccine. AIDS Res Hum Retroviruses 1994, 11:1433-1441.
6. Eu S, Santoro JC, Filler OH, et al.: Use of DNAs expressing HIV-1 env and noninfectious HIV-1 particles to raise antibody responses in mice. Virology 1995, 209:147-154.
7. Wang B, Boyer JD, Srikantan V, ct al.: Induction of humoral and cellular immune responses to the human immunodeficiency type 1 virus in nonhuman primates by in vivo DNA inoculation. Virology 1995, 211:102-112.
8. Culler BR, Greene WC: Regulatory pathways governing HIV-1 replication. Cell 1989, 58:423-426.
9. Desrosiers RC: HIV with multiple gene deletions as a live attenuated vaccine for AIDS. AIDS Res Hum Retroviruses 1992, 8:411-412.
10. Gabuzda DH, Lawrence K, Langholl E, et al.: Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J Virol 1992, 66:6489-6495.
11. Gibbs JS, Regier DA, Desrosiers RC: Construction and in vitro properties of HIV-1 mutants with deletions in nonessential genes. AIDS Res Hum Retroviruses 1994, 10:343-350.
12. Aldrovaneli GM, Zack JA: Replication and pathogenicity of Human immunodeficiency virus type 1 accessory gene mutants in SCID-hu mice. J Virol 1996, 70:1505-1511.
13. Trono D: HIV accessory proteins: leading roles for the supporting cast. Cell 1995, 82:189-192.
14. Ameisen JC, Guy B, Loche M, et al.: Antibody response to the HIV-1 regulatory gene products nef, vif and vpr in HIV-1 infected seronegative individuals. 5th lnternational Conference on AIDS, June 1989 [abstract 5:533].
15. Lamhamedi-Cherradi S, Culmann-Penciolelli B, Guy B, et al.: Qualitative and quantitive analysis of human cytotoxic T-lymphocyte responses to HIV-1 proteins. AIDS 1992, 6:1249-1258.
16. Arya SK, Gallo RC: Three novel genes of human T-lymphotropic virus type III: immune reactivity of their products with sera from acquired immune deficiency syndrome patients. Proc Natl Acad Sci U S A 1986, 83:2209-2215.
17. Garrett ED, Tiley L, Cullen B: rev activates expression of the human immunodeficiency virus type 1 vif and vpr gene products. J Virol 1991, 65:1653-1657.
18. Schwartz S, Felber B, Pavlakis G: Expressions of human immunodeficiency virus type 1 vif and vpr mRNAs is rev-dependent and regulated by splicing. Virology 1991, 183:677-686.
19. Sodroski JW, Goh C, Rosen C, et al.: Replicative and cytopathic potential of HTLV-III/LAV with sor gene deletions. Science 1986, 231:1549-1551.
20. Myers G, Korber B, Berzofsky JA, et al.: Human Retroviruses and AIDS 1993. Los Alamos: Los Alamos National Laboratory, 1993.
21. Shacken BL, Luciw PA: Analysis of the vif gene of feline immunodeficiency virus. Virology 1994, 204:806-807.
22. Sova P, Ranst M, Gupta P, et al.: Conservation of an intact human immunodeficiency virus type 1 vif gene in vitro and in vivo. J Virol 1995, 69:2557-2564.
23. Wieland U, Kratschmann H, Kehm R, et al.: Antigenic domains of the HIV-1 vif protein as recognized by human sera and murine monoclonal antibodies. AIDS Res Hum Retroviruses 1991, 7:861-867.
24. Michael NL, Chang G, D'Arcy LA, et al.: Defective accessory genes in a human immunodeficiency virus type 1-infected longterm surviror lacking recoverable virus. J Virol 1995, 69:4228-4256.
25. Kan NC, Franchini G, Wong-Staal F, et al.: Identification of HTLV-II/LAV sor gene product and detection of antibodies in human sera. Science 1986, 231:1555-1555.
26. Schwander S, Braun RW, Kuhn IE, et al.: Prevalence of antibodies to recombinant virion infectivity factor in the sera of prospectively studied patients with HIV-1 infection. J Med Virol 1992, 36:142-146.
27. Wieland U, Hartmann I, Suhr H, et al.: In vivo genetic variability of the HIV-1 vif gene. Virology 1994, 203:43-51.
28. Volsky DJ, Potash MJ, Simm M, et al.: The human immunodeficiency virus type 1 vif gene: the road from an accessory to an essential role in human immunodeficiency virus type 1 replication. Curr Topics Microbiol Immunol 1995, 193:157-168.
29. Velpandi A, Monken C, Srinivasan A: Development of RD-tat cell lines: use in HIV recombination studies. J Virol Methods 1990, 29:291-502.
30. Velpandi A, Ugen KE, Fernandes L. et al.: Analysis of genetic heterogeneity, antigenicity and biological characteristics of HIV-1 in a maternal transmitter and non transmitter patient pair. DNA Cell Biol 1996, 15:571-580.
31. zr6 mutants are defective in binding to peripheral blood mononuclear cells and in internalizalion. DNA Cell Biol 1996 , 15:353 -361.
32. Mahalingam S, Mamata P, Collman RG, et al.: The carboxy terminal domain is essential for stability not for virion incorporation of HIV-1 vpr into virus particles. Virology 1995, 214:647-652.
33. Wang B, Boyer JD, Ugen KE, et al.: Nucleic acid-based immunization against HIV-1 : induction of protective in vivo immune responses. AIDS 1995, 9 (suppl A):S159-S170.
34. IIIB env specific cytotoxic T lymphocytes. J Virol 1995, 67:3409-3411.
35. Dougherty JP, Temin MM: Determination of the rate of base pair substitution and insertion mutations in retrovirus replicalion. J Virol 1988, 62:2817-2822.
36. Fisher AG, Ensoli B, Looney D, et al.: Biologically diverse molecular variants within a single HIV-1 isolate. Nature 1988, 334:144-447.
37. Meyerhans A, Cheynier K, Albert I, et al.: Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations. Cell 1989,58:901-910.
38. Pircher H, Moskolindis D, Rohrer U, et al.: Viral escape by selection of cytotoxic T cell resistant variants in vivo. Nature 1990, 346:629-633 .
39. Reitz MS, Wilson C , Naugle C, et al.: Generation of a neutralization resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene. Cell 1988, 54:57-68.
40. Wolfs H, Zwart G, Bakker M, et al.: Naturally occurring mutations within HIV-I V3 genomic RNA lead to antigenic variation dependent on a single amino acid substitution. Virology 1991, 185:195-205.
41. Goncalves I, Jallepalli P, Gabuzda DH: Suhcellular localization of the Vif protein of human immunodeficiency virus type 1. J Virol 1994, 68:704-712.
42. Oberste MS, Gonda MA: Conservation of amino acid sequence motifs in lentivirus vif proteins. Virus Genes 1992, 6:95-112.
43. Myers G, Josephs SI, Rabson Ali, et al.: Human Retroviruses and AIDS 1988. Los Alamos: los Alamos National Laboratory 1988.
44. Guy B. Geist K, Dott K, et al.: A specific inhibitor of cysleine proteases impairs a vif dependent modification of human immunodeficiency virus type 1 env protein. J Virol 1991 65:1325-1331.
45. Borman AM, Quiillent C, Charneau P, et al.: Human immunodeficiency virus type 1 Vif-mutant particles from restrictive cells: role of vif in correct particle assembly. J Virol 1995, 69:2058-2067.
46. Sakai H, Shibata RJ, Sakuragi S, et al.: Cell dependent requirement of human immunodeficiency virus type 1 Vif protein for maturation of virus particles. J Virol 1993, 1663-1666.
47. Von Schwedler U, Song I, Aiken C, Irono D: Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J Virol 1993, 67:4947-4955.
48. Blane D, Patience C, Schulz H, et al.: Transcomplementation of vif HIV-1 mutants in CEM cells suggests that vif affects late steps of the viral life cycle. Virology, 1991,193:186-192.
49. Hevey M, Donehower IA: Complementation of human immunodeficiency virus type 1 vif mutants in some CD4 T cell lines. Virus Res 1994, 33:269-280.